Error loading player: No playable sources found
64255
Parallel Session 11: Progress in Gene Editing
Date
June 29, 2023
This product is not available for individual purchase, but it is available as part of the following products:
The Cell and Gene Therapy Products (CGTP) Symposium: Manufacturing, Quality and Regulatory Considerations enables the exchange of scientific ideas and dialogue with regulators that form the basis of evolving regulatory practices in the development of these diverse and innovative products…
Gene editing holds the promise to revolutionize medicine due to its potential to correct or disrupt target DNA sequences with a putative long-lasting effect. To realize the promise of these revolutionary medicines, appropriate quality control is needed to ensure targeting specificity to avoid unwanted off-target or on-target effects, such as translocation and integrations, and to address challenges related to formulation and delivery of a biologically active product.
In this session, we will discuss different technologies that lead to the improved specificity and control strategies to ensure product quality and safety. Examples of in vivo and ex vivo gene editing approaches that reached the clinic will be presented. Progress in innovative approaches, such as base editing, prime editing, and the emerging epigenetic editing technologies will be covered.
Session Speakers:
Regulatory Perspectives on Gene Therapies Incorporating Human Somatic Genome Editing
Zhaohui Ye, CBER, FDA
Analytical Challenges with Gene Regulation and Gene Editing In-vivo and Ex vivo Gene Therapies
Michael Moloney, Sangamo Therapeutics
Epigenetic Editing: New Frontier for Genetic Medicines
Raj Poudel, Tune Therapeutics
Additional Panelists:
Barbara Bonamassa, AIFA
Premanjali Lahiri, Graphite Bio
In this session, we will discuss different technologies that lead to the improved specificity and control strategies to ensure product quality and safety. Examples of in vivo and ex vivo gene editing approaches that reached the clinic will be presented. Progress in innovative approaches, such as base editing, prime editing, and the emerging epigenetic editing technologies will be covered.
Session Speakers:
Regulatory Perspectives on Gene Therapies Incorporating Human Somatic Genome Editing
Zhaohui Ye, CBER, FDA
Analytical Challenges with Gene Regulation and Gene Editing In-vivo and Ex vivo Gene Therapies
Michael Moloney, Sangamo Therapeutics
Epigenetic Editing: New Frontier for Genetic Medicines
Raj Poudel, Tune Therapeutics
Additional Panelists:
Barbara Bonamassa, AIFA
Premanjali Lahiri, Graphite Bio
General
Tracks
Related Products
Parallel Session 7: Unique Challenges of Stability Testing for Cell and Gene Therapy Products
Cell and Gene Therapy programs are progressing from early academic settings to commercial manufacturing at increasingly faster pace and in greater numbers. These therapies are complex, difficult to manufacture in large quantities, and involve many bespoke technologies to make, test and release…
Plenary Session 12: Updates in the Regulatory Landscape for Cell & Gene Therapy Products
Several cell and gene therapy products have received marketing approval from health authorities and, with that, a more complete picture is now emerging about the regulatory CMC requirements to commercialize these products…
Keynote Presentation
Gene Therapy Drug Development for Ultra-Rare Disease: Challenges & Opportunities
Parallel Session 6: Allogeneic Cell-based Therapies: Next Frontier in Advanced Therapies
Allogeneic cell therapies have a potential to revolutionize life-saving Cell and Gene therapy (CGT) field by removing the bottlenecks created by long scheduling delays, lengthy manufacturing times and potential product failures of autologous cell therapies…
